NASDAQ:HSKA - Heska Stock Price, Forecast & News

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Heska Corp (NASDAQ:HSKA) announced its earnings results on Tuesday, February, 25th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by $0.21. The medical research company earned $33.77 million during the quarter, compared to analyst estimates of $34.29 million. Heska had a net margin of 3.15% and a return on equity of 3.17%. View Heska's Earnings History.

Heska is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Heska.

Heska updated its FY 2020 Pre-Market earnings guidance on Tuesday, February, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-145 million, compared to the consensus revenue estimate of $141.76 million.

8 analysts have issued 12 month price objectives for Heska's stock. Their forecasts range from $68.00 to $107.00. On average, they expect Heska's stock price to reach $88.80 in the next twelve months. This suggests that the stock has a possible downside of 10.9%. View Analyst Price Targets for Heska.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Heska.

Headlines about HSKA stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Heska earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Heska.

Heska saw a decline in short interest in the month of February. As of February 14th, there was short interest totalling 859,800 shares, a decline of 7.9% from the January 30th total of 933,700 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is presently 11.9 days. Currently, 12.3% of the company's shares are short sold. View Heska's Current Options Chain.

Some companies that are related to Heska include Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Oxford Immunotec Global (OXFD), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Riot Blockchain (RIOT), Trinity Biotech (TRIB), GeneNews (GNWSF), Arca Biopharma (ABIO) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Broadcom (AVGO), Biogen (BIIB), Netflix (NFLX), Western Digital (WDC), Exelixis (EXEL), Gilead Sciences (GILD), Micron Technology (MU), Exxon Mobil (XOM), AT&T (T) and Amgen (AMGN).

Heska's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (13.32%), Standard Life Aberdeen plc (3.78%), Riverbridge Partners LLC (3.70%), State Street Corp (3.63%), FMR LLC (3.05%) and SG Capital Management LLC (2.33%). Company insiders that own Heska stock include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Nancy Wisnewski, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska.

HSKA stock was sold by a variety of institutional investors in the last quarter, including SG Capital Management LLC, Standard Life Aberdeen plc, SG Americas Securities LLC, State Street Corp, Grace & White Inc. NY, Jane Street Group LLC, Citigroup Inc. and US Bancorp DE. View Insider Buying and Selling for Heska.

HSKA stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., Public Sector Pension Investment Board, Aviva PLC, Russell Investments Group Ltd., Geode Capital Management LLC, Great West Life Assurance Co. Can, Fred Alger Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Heska.

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HSKA stock can currently be purchased for approximately $99.69.

Heska has a market capitalization of $780.37 million and generates $127.45 million in revenue each year. The medical research company earns $5.85 million in net income (profit) each year or $1.42 on an earnings per share basis. Heska employs 347 workers across the globe.View Additional Information About Heska.

The official website for Heska is http://www.heska.com/.

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]